Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > High on Nano: Cannabinoid Nanoparticles to Treat the Primary Cause of Heart Attack and Stroke

Abstract:
Only two years ago an American-Dutch research effort was the first trialling nanotherapy in cardiovascular patients. Since then they took some remarkable steps towards the use of a combination of endogenous nanoparticles and cannabinoids to treat atherosclerosis. Ground-breaking projects demand innovative ways to create publicity and gather funding. The non-profit organization High on Nano aims to crowd fund a documentary about this topic to support the research.

High on Nano: Cannabinoid Nanoparticles to Treat the Primary Cause of Heart Attack and Stroke

Amsterdam, Netherlands | Posted on December 4th, 2013

The development of nanotechnologies to encapsulate drugs in tiny nanoparticles has witnessed tremendous growth in the last two decades. These nanoparticles are designed for accurate delivery of imaging agents and/or drugs at diseased sites, increasing precision hits while hopefully lowering side effects. Unfortunately the large amount of promising research projects -mainly focusing on oncologic targets- only reported limited clinical successes so far.

For the exploration of nanotechnology in cardiovascular medicine the Dutch chemist Willem Mulder founded the Nanomedicine Laboratory at the Icahn School of Medicine at Mount Sinai in 2006. The nanoparticle platforms his team develops are designed to specifically target atherosclerotic plaques, the underlying cause of cardiovascular disease. In cooperation with the Academic Medical Center in Amsterdam the first-in-man trials with synthetic nanoparticles were initiated already in 2011. In preclinical studies the exploitation of endogenous nanoparticles has shown promise in the context of cardiovascular disease, as such nanoparticles exhibit a natural affinity for atherosclerotic plaques. These particles create an attractive and natural drug delivery platform for atherosclerotic targets.

One of the potent anti-atherosclerotic drug classes they investigate is cannabinoids. In 2005 a seminal study published in the journal Nature demonstrated that low dose oral cannabinoid therapy reduces the progression of atherosclerosis in mice. However, research activity in this area has been relatively subdued. This may be -in part- attributed to psychotropic side effects, and poor specificity and bioavailability of orally administered cannabinoids. To overcome these limitations, nanoparticle formulations may offer an attractive alternative.

Atherosclerosis is also known as ‘hardening' of the arteries. It is a result of genetics, high cholesterol, high blood pressure and smoking cigarettes. It is a common underlying cause of cardiovascular diseases, including heart attack and stroke, and represents the highest expenditure of the world health care (app €198 billion in EU and $300 billion in the US).

Every year about 1,3 million people die from cardiovascular disease in the US and 1,6 million in Europe.

In patients who suffered a heart attack the recurrence risk of an acute coronary syndrome is high, particularly within the first three years when recurrence rates are up to over 20%.

The Dutch Non-profit organization High on Nano was founded on October 28th. Their goal is to popularise the work of Willem Mulder and his teams by developing a documentary (series) about his work.

####

About www.HighonNano.com
To support this project, non-profit organization High on Nano was recently founded. Their aim is to familiarize the general public with this exciting field and establish innovative mechanisms to help fund the research. The first step is crowd funding a documentary to show the world what is going on in the field of 21st century nanomedicine. They hope this process, and the resulting publicity, ultimately open up ways to fund part of the research.

For more information, please click here

Contacts:
Gert van Kempen
Chairman
Non-profit Organization High on Nano

http://www.facebook.com/HighonNano

Copyright © www.HighonNano.com

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related Links

Article:

Clinical trials:

Clinical trials:

Article:

Abstract:

Related News Press

News and information

Leti IEDM 2016 Paper Clarifies Correlation between Endurance, Window Margin and Retention in RRAM for First Time: Paper Presented at IEDM 2016 Offers Ways to Reconcile High-cycling Requirements and Instability at High Temperatures in Resistive RAM December 6th, 2016

Tokyo Institute of Technology research: 3D solutions to energy savings in silicon power transistors December 6th, 2016

Physicists decipher electronic properties of materials in work that may change transistors December 6th, 2016

Infrared instrumentation leader secures exclusive use of Vantablack coating December 5th, 2016

Construction of practical quantum computers radically simplified: Scientists invent ground-breaking new method that puts quantum computers within reach December 5th, 2016

Videos/Movies

Infrared instrumentation leader secures exclusive use of Vantablack coating December 5th, 2016

2-D material a brittle surprise: Rice University researchers finds molybdenum diselenide not as strong as they thought November 14th, 2016

Keystone Nano Announces The US FDA Has Awarded Orphan Drug Designation For Ceramides For The Treatment Of Liver Cancer November 8th, 2016

VC/Funding/Angel financing/Loans/Leases/Crowdfunding

Harris & Harris Group Issues Letter to Shareholders and Information for Shareholder Call on Tuesday, November 15, 2016 November 14th, 2016

Harris & Harris Group Issues Business Update and Reports Financial Statements as of September 30, 2016 November 9th, 2016

Nanomedicine

Fast, efficient sperm tails inspire nanobiotechnology December 5th, 2016

Journal Nanotechnology Progress International (JONPI) Volume 6, issue 2 coming out soon! December 5th, 2016

UTSA study describes new minimally invasive device to treat cancer and other illnesses: Medicine diffusion capsule could locally treat multiple ailments and diseases over several weeks December 3rd, 2016

Nanobiotix Provides Update on Global Development of Lead Product NBTXR3: Seven clinical trials across the world: More than 2/3 of STS patients recruited in the “act.in.sarc” Phase II/III trial: Phase I/II prostate cancer trial now recruiting in the U.S. November 28th, 2016

Announcements

Leti IEDM 2016 Paper Clarifies Correlation between Endurance, Window Margin and Retention in RRAM for First Time: Paper Presented at IEDM 2016 Offers Ways to Reconcile High-cycling Requirements and Instability at High Temperatures in Resistive RAM December 6th, 2016

Tokyo Institute of Technology research: 3D solutions to energy savings in silicon power transistors December 6th, 2016

Physicists decipher electronic properties of materials in work that may change transistors December 6th, 2016

Infrared instrumentation leader secures exclusive use of Vantablack coating December 5th, 2016

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project